In other recent news, Fractyl Health Inc. reported its second-quarter 2025 earnings, highlighting a notable rise in research and development expenses, which contributed to a widened net loss compared to the previous year. Despite these financial challenges, Fractyl Health has successfully extended its cash runway into 2026, providing some reassurance about its financial stability. In response to these developments, Canaccord Genuity adjusted its price target for Fractyl Health's stock, lowering it from $12 to $6, while maintaining a Buy rating. The firm described the company's financial report as "incremental" and noted that key timelines for Fractyl Health's clinical programs are still on schedule. These updates reflect a cautious yet optimistic outlook from analysts regarding the company's future prospects.